{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:05:40Z","timestamp":1773050740836,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.yebeh.2021.108031","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T13:38:27Z","timestamp":1620913107000},"page":"108031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"PA","title":["Which treatment strategy in patients with epilepsy with focal seizures uncontrolled by the first anti-seizure medication?"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2416-147X","authenticated-orcid":false,"given":"Gaetano","family":"Zaccara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-1577","authenticated-orcid":false,"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.108031_b0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2021.108031_b0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4065\/71.6.576","article-title":"Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota","volume":"71","author":"Hauser","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.yebeh.2021.108031_b0015","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108031_b0020","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second-generation antiseizure medications: impact and future perspectives","volume":"19","author":"Perucca","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.108031_b0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2165\/00003495-200666140-00004","article-title":"Combination therapy in epilepsy: when and what to use","volume":"66","author":"Kwan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2021.108031_b0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on?","volume":"9","author":"Kwan","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108031_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2003.09.007","article-title":"Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial","volume":"57","author":"Beghi","year":"2003","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108031_b0040","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.yebeh.2013.05.038","article-title":"Alternative monotherapy or add-on therapy in patients with epilepsy whose seizures do not respond to the first monotherapy: an Italian multicenter prospective observational study","volume":"28","author":"Millul","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108031_b0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2018.11.018","article-title":"Substitution has better efficacy than add-on therapy for patients with focal epilepsy after their first antiepileptic drug treatments fail","volume":"64","author":"Wang","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108031_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106939","article-title":"Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice","volume":"104","author":"Verrotti","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108031_b0055","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0022-3565(25)13268-0","article-title":"Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction","volume":"247","author":"Bourgeois","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2021.108031_b0060","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","article-title":"Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed","volume":"41","author":"Deckers","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108031_b0065","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17512433.2018.1500895","article-title":"A viewpoint on rational and irrational fixed-drug combinations","volume":"11","author":"B\u0142aszczyk","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.108031_b0070","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1528-1157.1998.tb01356.x","article-title":"Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?","volume":"39","author":"Besag","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108031_b0075","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2021.108031_b0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.eplepsyres.2018.08.011","article-title":"Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures","volume":"147","author":"Abou-Khalil","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108031_b0085","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2021.108031_b0090","unstructured":"NICE Guidelines. https:\/\/www.nice.org.uk\/guidance\/cg137\/resources\/epilepsies-diagnosis-and-management-35109515407813 (Accessed on February, 2021)"},{"key":"10.1016\/j.yebeh.2021.108031_b0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1212\/WNL.0000000000005755","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108031_b0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2016.07.001","article-title":"Guideline conform initial monotherapy increases in patients with focal epilepsy: A population-based study on German health insurance data","volume":"41","author":"Ertl","year":"2016","journal-title":"Seizure"},{"issue":"Doc09","key":"10.1016\/j.yebeh.2021.108031_b0105","article-title":"Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs","volume":"15","author":"Groth","year":"2017","journal-title":"Ger Med Sci"},{"key":"10.1016\/j.yebeh.2021.108031_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106503","article-title":"Prescription patterns of antiepileptic drugs for adult patients with newly diagnosed focal epilepsy from 2006 to 2017 in Japan","volume":"169","author":"Chen","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108031_b0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yebeh.2018.05.019","article-title":"Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: A US database analysis","volume":"85","author":"Faught","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108031_b0120","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/epi.13340","article-title":"Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment","volume":"57","author":"Klitgaard","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108031_b0125","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2021.108031_b0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-200408000-00006","article-title":"Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs","volume":"26","author":"Contin","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2021.108031_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234070","article-title":"Polygonogram and isobolographic analysis of interactions between various novel antiepileptic drugs in the 6-Hz corneal stimulation-induced seizure model in mice","volume":"15","author":"Luszczki","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.yebeh.2021.108031_b0140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.seizure.2009.06.009","article-title":"Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model","volume":"18","author":"Dudra-Jastrzebska","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108031_b0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1059-1311(03)00185-7","article-title":"Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models","volume":"13","author":"Sills","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108031_b0150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.euroneuro.2005.03.005","article-title":"Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice","volume":"15","author":"Luszczki","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.yebeh.2021.108031_b0155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eplepsyres.2009.06.003","article-title":"Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model","volume":"86","author":"Wojda","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108031_b0160","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1212\/WNL.0000000000002545","article-title":"Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis","volume":"86","author":"Lattanzi","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108031_b0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108031_b0170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.seizure.2006.05.001","article-title":"Predicting drug-resistant patients who respond to add-on therapy with levetiracetam","volume":"15","author":"Kinirons","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108031_b0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nbd.2018.03.015","article-title":"A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy","volume":"115","author":"Ruffolo","year":"2018","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108031_b0180","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/ane.12691","article-title":"Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy","volume":"135","author":"Baulac","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.108031_b0185","unstructured":"Lamotrigine SPC: https:\/\/www.medicines.org.uk\/emc\/product\/6092\/smpc#gref (Accessed on March 2021)"},{"key":"10.1016\/j.yebeh.2021.108031_b0190","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fphar.2015.00242","article-title":"Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer","volume":"6","author":"Prabhavalkar","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2021.108031_b0195","unstructured":"FDA. Lamotrigine. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Lamictal\/pdf\/LAMICTAL-PI-MG.PDF)FDA. (Accessed on March 2021)."},{"key":"10.1016\/j.yebeh.2021.108031_b0200","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2021.108031_b0205","doi-asserted-by":"crossref","first-page":"881","DOI":"10.17219\/acem\/69132","article-title":"Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in a mouse tonic-clonic seizure model","volume":"27","author":"Kondrat-Wr\u00f3bel","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.yebeh.2021.108031_b0210","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s43440-020-00117-y","article-title":"Sub-additive (antagonistic) interaction of lacosamide with lamotrigine and valproate in the maximal electroshock-induced seizure model in mice: an isobolographic analysis","volume":"72","author":"\u0141uszczki","year":"2020","journal-title":"Pharmacol Rep"},{"issue":"9107","key":"10.1016\/j.yebeh.2021.108031_b0215","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(05)60613-7","article-title":"Lamotrigine and topiramate may be a useful combination","volume":"351","author":"Stephen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2021.108031_b0220","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0140-6736(93)93048-6","article-title":"Interaction of lamotrigine with sodium valproate","volume":"341","author":"Panayiotopoulos","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2021.108031_b0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1059-1311(05)80208-0","article-title":"Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy","volume":"3","author":"Ferrie","year":"1994","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108031_b0230","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(94)90741-2","article-title":"Lamotrigine in infantile spasms","volume":"344","author":"Veggiotti","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2021.108031_b0235","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate?","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108031_b0240","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1157.1999.tb00832.x","article-title":"The efficacy of valproate lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction","volume":"40","author":"Pisani","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108031_b0245","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archneur.58.8.1264","article-title":"Effect of divalproex-lamotrigine combination therapy in frontal lobe seizures","volume":"58","author":"McCabe","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2021.108031_b0250","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1528-1157.1999.tb00831.x","article-title":"Adding lamotrigine to valproate: incidence of rash and other adverse effects","volume":"40","author":"Faught","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108031_b0255","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0140-6736(93)91398-6","article-title":"Disabling tremor after lamotrigine with sodium valproate","volume":"342","author":"Reutens","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2021.108031_b0260","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.seizure.2020.10.024","article-title":"Carbamazepine -An oldie but a goodie-A clinician's perspective","volume":"83","author":"Beran","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108031_b0265","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000444452","article-title":"Isobolographic analysis of interaction for three-drug combination of carbamazepine, phenobarbital and topiramate in the mouse maximal electroshock-induced seizure model","volume":"97","author":"Luszczki","year":"2016","journal-title":"Pharmacology"},{"key":"10.1016\/j.yebeh.2021.108031_b0270","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2001.0633","article-title":"Interaction of topiramate with carbamazepine: two case reports and a review of clinical experience","volume":"11","author":"Mack","year":"2002","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108031_b0275","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00309-6","article-title":"Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction","volume":"48","author":"Sisodiya","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108031_b0280","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/WNF.0b013e3181ac3615","article-title":"Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate","volume":"32","author":"Deutsch","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2021.108031_b0285","first-page":"1","article-title":"Hypoxic respiratory failure due to hyperammonemic encephalopathy induced by concurrent use of valproic acid and topiramate, a case report and review of the literature","volume":"25","author":"Raru","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.yebeh.2021.108031_b0290","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2710.2008.00943.x","article-title":"Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy","volume":"33","author":"Knudsen","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.yebeh.2021.108031_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105894","article-title":"Valproic acid and zonisamide induced hyperammonemic encephalopathy","volume":"196","author":"Ilieva","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.yebeh.2021.108031_b0300","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1046\/j.1528-1157.2002.34301.x","article-title":"Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis","volume":"43","author":"Borowicz","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108031_b0305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00210-007-0144-z","article-title":"Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application","volume":"375","author":"Luszczki","year":"2007","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.yebeh.2021.108031_b0310","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00002826-199402000-00003","article-title":"Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice","volume":"17","author":"Chez","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2021.108031_b0315","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.124","article-title":"Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action","volume":"3","author":"Soares-da-Silva","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108031_b0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00210-005-1088-9","article-title":"Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model","volume":"372","author":"Luszczki","year":"2005","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108031_b0325","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0278-5846(03)00166-0","article-title":"Asterixis and toxic encephalopathy induced by gabapentin","volume":"28","author":"Sechi","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2021.108031_b0330","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/17425255.2016.1154534","article-title":"Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors","volume":"12","author":"Supuran","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.yebeh.2021.108031_b0335","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ane.13025","article-title":"Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis","volume":"139","author":"Lattanzi","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.108031_b0340","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.seizure.2018.08.007","article-title":"Long-term retention rates of antiepileptic drugs used in acute seizures","volume":"61","author":"Toledo","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108031_b0345","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11910-016-0678-x","article-title":"Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide","volume":"16","author":"Brodie","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.yebeh.2021.108031_b0350","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/14737175.2020.1840979","article-title":"The comorbidities of epilepsy explained","volume":"20","author":"Mula","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2021.108031_b0355","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ane.13249","article-title":"Drug treatments in patients with cardiac diseases and epilepsy","volume":"142","author":"Zaccara","year":"2020","journal-title":"Acta Neurol Scand"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:40:42Z","timestamp":1761504042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021002651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":71,"alternative-id":["S1525505021002651"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108031","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which treatment strategy in patients with epilepsy with focal seizures uncontrolled by the first anti-seizure medication?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108031"}}